ReviewOncoimmunology2026
Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics.
Review in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy.International journal of molecular sciences · 2026Review
- Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance.bioRxiv : the preprint server for biology · 2026Article
- T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decades, cancer immunotherapy has evolved into clinical practice, with bispecific T cell engagers (TCEs) and other higher-order multispecific immunotherapeutics emerging as approaches for precision immune modulation. These engineered antibodies redirect immune effector cells toward tumor targets, thereby eliciting coordinated antitumor immune responses. While substantial clinical success has been achieved in hematologic malignancies, major challenges, such as limited activity in solid tumors, continue to constrain broader application. In this Trial Watch, we summarize recent preclinical advances in the design and optimization of TCEs and multispecific immune engager platforms together with available clinical trial data. We further examine key pharmacokinetic, safety, resistance, and manufacturing considerations in immune engager development. Collectively, these findings highlight the increasing versatility of immune cell-redirecting immunotherapies and their pivotal role in shaping the next generation of precision cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.